Researchers at the Johns Hopkins Kimmel Cancer Center's Ludwig Center developed a new treatment that selectively targets ...

Orum Therapeutics Appoints Chad May as Chief Scientific Officer to Drive Degrader-Antibody Conjugate Innovation and Programs ...

Neoantigens are unique markers that distinguish only cancer cells. By adding B cell reactivity, cancer vaccines can move ...

Flagship Pioneering, a scientific innovation engine for transformative platforms and products, today announced a research program under its strategic collaboration with Pfizer whereby Flagship-founded ...

Flagship Pioneering, a scientific innovation engine for transformative platforms and products, today announced a research program under its strategic collaboration with Pfizer whereby Flagship-founded ...

For starters, she pointed out that standard CAR-T therapy involves a lymphodepletion regimen with cyclophosphamide and ...

The decision to end the programme comes 18 months after Genmab's former partner for the acasunlimab, BioNTech, pulled out of ...

Abbvie Inc. signed a $1.1 billion New Year’s Eve deal with China’s Zelgen Biopharmaceuticals Co. Ltd., gaining ex-China ...

At the recent American Society of Hematology annual meeting, researchers presented preclinical data examining how ...

Back in the day, gyms were places where (mostly) men could lift, grunt, and sweat a lot. Old-school outfits like Gold’s Gym ...

Researchers at the Johns Hopkins Kimmel Cancer Center’s Ludwig Center developed a new treatment that selectively targets ...

Antigen-driven TCR signaling in the epidermis during CD8+ TRM differentiation results in a lower TGFβ requirement for persistence and increased proliferative capacity that together enhance epidermal ...